

LAHIVE  
&  
COCKFIELD  
L L P

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
lc@lahive.com



JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
GIULIO A. DeCONTI, JR.  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DeANN F. SMITH  
DEBRA J. MILASINCIC, Ph.D.  
WILLIAM A. SCOFIELD, Jr.  
SIBLEY P. REPPERT  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER  
MEGAN E. WILLIAMS, Ph.D.  
HATHAWAY P. RUSSELL \*  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.

DANIELLE L. HERRITT  
EUIHOON LEE \*\*  
MANEESH GULATI  
CYNTHIA M. SOROOS  
PETER W. D'NI, Ph.D.  
MICHAEL J. BASTIAN, Ph.D.  
CHRISTOPHER J. MCKENNA  
VINCENT P. LOCCISANO  
JAMES M. MCKENZIE

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
JEANNE M. DIGIORGIO  
CYNTHIA L. KANIK, Ph.D.  
JOHN D. LANZA

PATENT AGENTS  
JONATHAN M. SPARKS, Ph.D.  
ANDRINA WILLIAMS ZINK  
CRISTIN E. HOWLEY, Ph.D.  
JILL A. MELLO, Ph.D.  
CHRISTOPHER E. DRABIK  
JAMES H. VELEMA

TECHNICAL SPECIALISTS  
CATHERINE M. BISHOP  
JACOB G. WEINTRAUB  
DEBORAH L. NAGLE, Ph.D.  
A. JACQUELINE WIZEMAN, Ph.D.  
BRIAN C. TRINQUE, Ph.D.  
CHRISTOPHER R. COWLES, Ph.D.  
W. ELANA WANG  
CYNTHIA M. GILBERT  
MEAGHAN L. RICHMOND, Ph.D.

\* Admitted in TX only  
\*\* Admitted in CT only

November 19, 2004

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/810,767  
For: *N-(4-(4-METHYLTHIAZOL-5-YL) PYRIMIDIN-2-YL)-N-PHENYLAMINES*  
*AS ANTIPROLIFERATIVE COMPOUNDS*  
Inventors: Wang, Shudong, *et al.*  
Filed: March 26, 2004  
Our Ref. No.: CCI-029CN

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form SB/08;
3. Copies of references cited in PTO Form SB/08 (6);
4. A copy of the International Search Report; and
5. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on:

November 22, 2004  
Date  
  
Cynthia M. Soroos, Registration No. 53,623

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

Cynthia M. Soroos  
Registration No. 53,623  
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Wang, Shudong, *et al.*

Serial No.: 10/810,767

Filed: March 26, 2004

For: *N-(4-(4-METHYLTHIAZOL-5-YL) PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS*

Attorney Docket No.: CCI-029CN

Group Art Unit: 1614

Examiner: Not Yet Assigned

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

November 22, 2004

Date of Signature and of Mail Deposit

By:

  
Cynthia M. Soroos  
Registration No. 53,623  
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form SB/08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. Reference ID Nos. A2, A3 and A6 were cited in an International Search Report dated December 4, 2002 during the prosecution of PCT/GB 02/04383 which corresponds to the above referenced application. A copy of the report and each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP




Cynthia M. Soroos  
Registration No. 53,623  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: November 22, 2004

GAD/CLK/CMS/rl  
Enclosures



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/810,767
				Filing Date	March 26, 2004
				First Named Inventor	Wang, Shudong
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	CCI-029CN

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	A1	WO 95/09847 A1	04-13-1995	CIBA-GEIGY Corp.		
	A2	WO 97/19065 A1	05-29-1997	Celltech Therapeutics Ltd.		
	A3	WO 01/72745 A1	10-04-2001	Cyclacel Limited		
	A4	EP 0233461 B2	08-26-1987	American Cyanamid Co.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A5	Paul, R., et al. "Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors." <i>J Med Chem.</i> 1993 Sep 17; 36(19):2716-25.	
	A6	Zimmermann, J., et al. "Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)." <i>Arch Pharm (Weinheim)</i> . 1996 Jul; 329(7): 371-6.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--